Gemini Therapeutics And Avitide Enter Into Exclusive License Agreement

Gemini Therapeutics And Avitide Enter Into Exclusive License Agreement

By, Admin 12 December 2019

Avitide, Inc., The Industry Leader In The Discovery And Development Of Custom Affinity Purification Resins, Announces That It Has Entered Into An Exclusive License Agreement To Support The Development Of One Of Gemini Therapeutics' Therapeutic Programs."While Antibodies Have A Relatively Straightforward Path Through Development, Non-Antibody Biopharmaceuticals Do Not. We Anticipated Challenges And Partnered With Avitide To De-Risk Our Lead Program And Accelerate Preclinical Development. Avitide Supplied Resins For Process Development, Toxicology Lot And Cgmp Manufacturing In Sync With Our Cdmo Timelines. Given The Success Of Our First Partnership, We Look To Expand The Relationship To Include Other Therapeutic Programs Within The Gemini Portfolio," Said Scott Lauder, Gemini Therapeutics' Chief Technology Officer.The License Agreement Grants Gemini Therapeutics Exclusive Rights To Specific Avitide Affinity Resins For Use In Preclinical, Clinical And Commercial Manufacturing. In Turn, Avitide Retains Exclusivity For The Manufacture And Supply Of The Affinity Resins To Gemini Therapeutics."Bioprocess Development Is Often On The Critical Path For Any Biopharmaceutical Drug Entering The Clinic; Establishing An Initial Purification Process That Does Not Have Line-Of-Sight To Commercial Manufacturing Can Carry Significant Costs And Regulatory Risks. Gemini Recognized These Risks From The Onset And Elected To Work With Avitide To De-Risk Their Overall Development Path. We Look Forward To Continuing The Relationship With Gemini To Help Get This Important Therapy To The Clinic," Said Kevin Isett, Avitide'S Chief Executive Officer.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!